Download Files:
Lixumistat (hydrochloride)
SKU
HY-136093-Get quote
Category Reference compound
Tags AMPK, Cancer; Neurological Disease, Epigenetics;PI3K/Akt/mTOR
Products Details
Product Description
– Lixumistat (HL271) hydrochloride (IM156 hydrochloride; HL156A hydrochloride), a chemical derivative of Metformin (HY-B0627), is a potent AMPK activator that increases AMPK phosphorylation. Lixumistat hydrochloride attenuates aging-associated cognitive impairment in animal model[1][2]. Lixumistat hydrochloride is a potent oxidative phosphorylation (OXPHOS) inhibitor which can be used for the research of solid tumors[3].
Web ID
– HY-136093
Shipping
– Room temperature
Applications
– Neuroscience-Neuromodulation
Molecular Formula
– C13H17ClF3N5O
References
– [1]Row H, et al. HL271, a novel chemical compound derived from metformin, differs from metformin in its effects on the circadian clock and metabolism. Biochem Biophys Res Commun. 2016 Jan 15;469(3):783-9.|[2]Bang E, et al. The Improving Effect of HL271, a Chemical Derivative of Metformin, a Popular Drug for Type II Diabetes Mellitus, on Aging-induced Cognitive Decline. Exp Neurobiol. 2018 Feb;27(1):45-56.|[3]Sun Young Rha, et al. Phase I study of IM156, a novel potent biguanide oxidative phosphorylation (OXPHOS) inhibitor, in patients with advanced solid tumors. Journal of Clinical Oncology 38(15_suppl):3590-3590.
CAS Number
– 1422365-52-3
Molecular Weight
– 351.76
SMILES
– N=C(N1CCCC1)NC(NC2=CC=C(OC(F)(F)F)C=C2)=N.[H]Cl
Clinical Information
– Phase 1
Research Area
– Cancer; Neurological Disease
Solubility
– 10 mM in DMSO
Target
– AMPK
Pathway
– Epigenetics;PI3K/Akt/mTOR
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.